Release 3 WGS Samples by Cohort

Processed WGS Totals for PD Cases and Controls

 PD CaseControl (Asymptomatic Individuals)Others
With Known MutationsNo Known MutationsWith Known MutationsNo Known MutationsWith Known MutationsNo Known Mutations
BioFIND2475224821
HBS20443514638503
LBD00541142413671247
LCC1816120315400
PDBP27857314535538111
PPMI5913505581728353
SURE-PD901690000
STEADY-PD31012270000
Total146918901615253814901415

 

WGS Known Sample Mutations

GBA: N370S (rs76763715); T369M (rs75548401); E326K (rs2230288)

LRRK2: G2019S (rs34637584); R1441C_T (rs33939927); R1441G_G (rs33939927)

SNCA: A53T (rs104893877); G51D (rs431905511); E46K (rs104893875); A30P (rs104893878)

APOE: 388T_C (rs429358); 526C_T (rs7412)

Targeted Proteomics Data

Additional participant variant data is now available in AMP PD Tier 2 data identifying the APOE genotype for all AMP PD participants. Apolipoprotein (Apo) E is produced under the direction of the APOE gene and is one of five main types of blood lipoproteins (A-E). AMP PD has evaluated participant’s WGS data to determine what combination of APOE forms (genotype) is present. The APOE gene exists in three different forms (alleles) – e2, e3, and e4 – with e3 being the most common allele, found in 60% of the general population.

AMP PD’s public dataset includes 3,095 participants with at least one copy of the APOE E4 gene, and 327 participants with two copies.